Heart medicine that lowers bad cholesterol
Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Surprising Findings
Alirocumab showed a 65% reduction in MACE and lower mortality, while Evolocumab only showed a 15% MACE reduction and no significant mortality benefit.
Evolocumab lowers cholesterol more (61% vs 46%), so it’s counterintuitive that Alirocumab shows much larger clinical benefits. Typically, greater LDL reduction correlates with better outcomes.
Practical Takeaways
If you’re at high risk for heart disease and your cholesterol isn’t controlled on statins, ask your doctor about PCSK9 inhibitors or Inclisiran.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Surprising Findings
Alirocumab showed a 65% reduction in MACE and lower mortality, while Evolocumab only showed a 15% MACE reduction and no significant mortality benefit.
Evolocumab lowers cholesterol more (61% vs 46%), so it’s counterintuitive that Alirocumab shows much larger clinical benefits. Typically, greater LDL reduction correlates with better outcomes.
Practical Takeaways
If you’re at high risk for heart disease and your cholesterol isn’t controlled on statins, ask your doctor about PCSK9 inhibitors or Inclisiran.
Publication
Journal
PLOS ONE
Year
2023
Authors
Tasnim F. Imran, Ali A. Khan, P. Has, A. Jacobson, S. Bogin, M. Khalid, Asim Khan, Samuel M Kim, S. Erqou, Gaurav Choudhary, K. Aspry, Wen-Chih Wu
Related Content
Claims (6)
Adding a drug called evolocumab to cholesterol-lowering statins can lower the chances of serious heart problems by 20% in people who already have heart disease.
A drug called alirocumab, given as a 75mg shot every couple of weeks, lowered bad cholesterol by almost half in people at high risk for heart problems over six months — a bit less than another similar drug, evolocumab.
A drug called Evolocumab helps lower the chance of serious heart problems like heart attacks and strokes in people at high risk — and it seems to work pretty well over about 8 months.
A drug called evolocumab, when given every two weeks, cuts bad cholesterol by more than 60% in people at high risk for heart problems — and that result has shown up consistently in several major studies.
A shot called inclisiran can cut bad cholesterol by more than half in people at high risk for heart problems, and it works with just two doses a year.